It has been shown that consuming SA (23 g) as part of a varied meal lowers postprandial glucose and hepatic glucose production in type 2 diabetic patients without increasing insulin secretion.34 However, there are still only a few clinical research using oral SA to treat type 2 diabetes, most of which are animal studies.35 When SUA is active, the state of the tissues defines the strength and direction of the change, and the outcome is shown by optimising the parameters that influence how well they work. The gene discussed is INS; the disease is type 2 diabetes mellitus.